JP6979595B2 - プロテインキナーゼ阻害剤としてのアミノチアゾール化合物 - Google Patents
プロテインキナーゼ阻害剤としてのアミノチアゾール化合物 Download PDFInfo
- Publication number
- JP6979595B2 JP6979595B2 JP2019568372A JP2019568372A JP6979595B2 JP 6979595 B2 JP6979595 B2 JP 6979595B2 JP 2019568372 A JP2019568372 A JP 2019568372A JP 2019568372 A JP2019568372 A JP 2019568372A JP 6979595 B2 JP6979595 B2 JP 6979595B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- alkyl
- salt according
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 **CC*c1nc(*)nc(Nc2nc(*)c[s]2)c1 Chemical compound **CC*c1nc(*)nc(Nc2nc(*)c[s]2)c1 0.000 description 2
- OJBDGAVTHDNNGB-UHFFFAOYSA-N CCN(CC1)CCN1c1cc(NCc2ncc(-c3ccncc3)[s]2)nc(C)n1 Chemical compound CCN(CC1)CCN1c1cc(NCc2ncc(-c3ccncc3)[s]2)nc(C)n1 OJBDGAVTHDNNGB-UHFFFAOYSA-N 0.000 description 1
- YUPVZEIZRAKIAK-UHFFFAOYSA-N CCN(CC1)CCN1c1cc(Nc2ncc(-c3ccccn3)[s]2)nc(C)n1 Chemical compound CCN(CC1)CCN1c1cc(Nc2ncc(-c3ccccn3)[s]2)nc(C)n1 YUPVZEIZRAKIAK-UHFFFAOYSA-N 0.000 description 1
- IMUILCLXLZZLHZ-UHFFFAOYSA-N CCN(CC1)CCN1c1cc(Nc2ncc(-c3cccnc3)[s]2)nc(C)n1 Chemical compound CCN(CC1)CCN1c1cc(Nc2ncc(-c3cccnc3)[s]2)nc(C)n1 IMUILCLXLZZLHZ-UHFFFAOYSA-N 0.000 description 1
- WFHXOLHVOPFWCI-UHFFFAOYSA-N CCN(CC1)CCN1c1cc(Nc2ncc(-c3cncnc3)[s]2)nc(C)n1 Chemical compound CCN(CC1)CCN1c1cc(Nc2ncc(-c3cncnc3)[s]2)nc(C)n1 WFHXOLHVOPFWCI-UHFFFAOYSA-N 0.000 description 1
- QTEPRIZDGABQIY-UHFFFAOYSA-N Cc1nc(N2CCN(CCF)CC2)cc(Nc2ncc(-c3cccnc3)[s]2)n1 Chemical compound Cc1nc(N2CCN(CCF)CC2)cc(Nc2ncc(-c3cccnc3)[s]2)n1 QTEPRIZDGABQIY-UHFFFAOYSA-N 0.000 description 1
- MDJCWIIMQFQPIA-UHFFFAOYSA-N Cc1nc(N2CCN(CCF)CC2)cc(Nc2ncc(-c3ccncc3)[s]2)n1 Chemical compound Cc1nc(N2CCN(CCF)CC2)cc(Nc2ncc(-c3ccncc3)[s]2)n1 MDJCWIIMQFQPIA-UHFFFAOYSA-N 0.000 description 1
- OXDKHCWZRQFLHF-UHFFFAOYSA-N Cc1nc(N2CCN(CCO)CC2)cc(Nc2ncc(-c3cccnc3)[s]2)n1 Chemical compound Cc1nc(N2CCN(CCO)CC2)cc(Nc2ncc(-c3cccnc3)[s]2)n1 OXDKHCWZRQFLHF-UHFFFAOYSA-N 0.000 description 1
- NOIDSVZCSPWJCJ-UHFFFAOYSA-N Cc1nc(N2CCN(CCO)CC2)cc(Nc2ncc(C3=CC=NCC#C3)[s]2)n1 Chemical compound Cc1nc(N2CCN(CCO)CC2)cc(Nc2ncc(C3=CC=NCC#C3)[s]2)n1 NOIDSVZCSPWJCJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518855P | 2017-06-13 | 2017-06-13 | |
| US62/518,855 | 2017-06-13 | ||
| PCT/US2018/037221 WO2018231910A1 (en) | 2017-06-13 | 2018-06-13 | Aminothiazole compounds as protein kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523348A JP2020523348A (ja) | 2020-08-06 |
| JP2020523348A5 JP2020523348A5 (enExample) | 2021-07-26 |
| JP6979595B2 true JP6979595B2 (ja) | 2021-12-15 |
Family
ID=64562741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568372A Active JP6979595B2 (ja) | 2017-06-13 | 2018-06-13 | プロテインキナーゼ阻害剤としてのアミノチアゾール化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10300061B2 (enExample) |
| EP (1) | EP3638237B1 (enExample) |
| JP (1) | JP6979595B2 (enExample) |
| KR (1) | KR102372288B1 (enExample) |
| CN (1) | CN110831596B (enExample) |
| AU (1) | AU2018284249B2 (enExample) |
| CA (1) | CA3064081C (enExample) |
| ES (1) | ES2949616T3 (enExample) |
| MX (1) | MX393992B (enExample) |
| MY (1) | MY201291A (enExample) |
| TW (1) | TWI667236B (enExample) |
| WO (1) | WO2018231910A1 (enExample) |
| ZA (1) | ZA202000107B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112469414A (zh) | 2018-05-25 | 2021-03-09 | 昂科库博疗法有限责任公司 | 作为新型候选抗癌药物的高效力tacc3抑制剂 |
| WO2021097352A1 (en) * | 2019-11-14 | 2021-05-20 | A2A Pharmaceuticals, Inc. | Isoxazole derivatives targeting tacc3 as anticancer agents |
| AU2021230288A1 (en) * | 2020-03-06 | 2022-09-01 | National Health Research Institutes | Pyrimidine compounds and their pharmaceutical uses |
| US11299489B1 (en) | 2020-11-19 | 2022-04-12 | National Health Research Institutes | Thiazole compounds as protein kinase inhibitors |
| WO2022221194A1 (en) * | 2021-04-12 | 2022-10-20 | A2A Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
| EP4499625A1 (en) | 2022-03-24 | 2025-02-05 | A2A Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006507302A (ja) * | 2002-10-30 | 2006-03-02 | メルク エンド カムパニー インコーポレーテッド | キナーゼ阻害剤 |
| CN101217954B (zh) | 2005-04-04 | 2013-07-10 | Ab科学公司 | 经取代的噁唑衍生物及其作为酪氨酸激酶抑制剂的用途 |
| EP1893607A4 (en) * | 2005-06-09 | 2010-07-21 | Merck Sharp & Dohme | CHECKPOINT KINASE INHIBITORS |
| GB0610909D0 (en) * | 2006-06-05 | 2006-07-12 | Merck Sharp & Dohme | Therapeutic treatment |
| WO2008033746A2 (en) * | 2006-09-11 | 2008-03-20 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| TW200906825A (en) * | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| US9255072B2 (en) * | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
| AU2012288900B2 (en) | 2011-07-27 | 2016-10-06 | Ab Science | Selective protein kinase inhibitors |
| WO2013143466A1 (zh) * | 2012-03-27 | 2013-10-03 | 广东东阳光药业有限公司 | 作为欧若拉激酶抑制剂的取代嘧啶衍生物 |
| CN106279143A (zh) * | 2015-05-11 | 2017-01-04 | 天津国际生物医药联合研究院 | 噻唑杂环类化合物及其制备方法和应用 |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
-
2018
- 2018-06-11 TW TW107120014A patent/TWI667236B/zh active
- 2018-06-13 MX MX2019014845A patent/MX393992B/es unknown
- 2018-06-13 AU AU2018284249A patent/AU2018284249B2/en active Active
- 2018-06-13 CA CA3064081A patent/CA3064081C/en active Active
- 2018-06-13 JP JP2019568372A patent/JP6979595B2/ja active Active
- 2018-06-13 MY MYPI2019006791A patent/MY201291A/en unknown
- 2018-06-13 CN CN201880039827.XA patent/CN110831596B/zh active Active
- 2018-06-13 EP EP18817380.1A patent/EP3638237B1/en active Active
- 2018-06-13 KR KR1020197038421A patent/KR102372288B1/ko active Active
- 2018-06-13 ES ES18817380T patent/ES2949616T3/es active Active
- 2018-06-13 US US16/007,417 patent/US10300061B2/en active Active
- 2018-06-13 WO PCT/US2018/037221 patent/WO2018231910A1/en not_active Ceased
-
2020
- 2020-01-08 ZA ZA2020/00107A patent/ZA202000107B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018284249A1 (en) | 2019-12-12 |
| AU2018284249B2 (en) | 2021-06-24 |
| MX393992B (es) | 2025-03-24 |
| MX2019014845A (es) | 2020-08-06 |
| BR112019026577A2 (pt) | 2020-06-23 |
| WO2018231910A1 (en) | 2018-12-20 |
| CA3064081C (en) | 2023-03-21 |
| CA3064081A1 (en) | 2018-12-20 |
| RU2019137573A3 (enExample) | 2021-07-23 |
| US10300061B2 (en) | 2019-05-28 |
| CN110831596A (zh) | 2020-02-21 |
| ZA202000107B (en) | 2020-12-23 |
| KR102372288B1 (ko) | 2022-03-08 |
| JP2020523348A (ja) | 2020-08-06 |
| EP3638237A1 (en) | 2020-04-22 |
| TW201906836A (zh) | 2019-02-16 |
| TWI667236B (zh) | 2019-08-01 |
| EP3638237A4 (en) | 2021-01-13 |
| NZ759327A (en) | 2021-08-27 |
| MY201291A (en) | 2024-02-15 |
| US20180353509A1 (en) | 2018-12-13 |
| EP3638237B1 (en) | 2023-04-19 |
| RU2019137573A (ru) | 2021-05-24 |
| BR112019026577A8 (pt) | 2023-04-11 |
| ES2949616T3 (es) | 2023-10-02 |
| KR20200014350A (ko) | 2020-02-10 |
| CN110831596B (zh) | 2025-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6979595B2 (ja) | プロテインキナーゼ阻害剤としてのアミノチアゾール化合物 | |
| EP2498607B1 (en) | Kinase inhibitors | |
| CN106883213B (zh) | 一种egfr和alk激酶的双重抑制剂 | |
| JP6883049B2 (ja) | アミノチアゾール化合物及びその使用 | |
| JP5779778B2 (ja) | Ｂｃｒ−ａｂｌの低分子のミリスチン酸エステル阻害剤及びその使用方法 | |
| CN105793260A (zh) | 作为用于治疗癌症的raf抑制剂的1-(5-叔丁基-2-芳基-吡唑-3-基)-3-[2-氟-4-[(3-氧代-4h-吡啶并[2，3-b]吡嗪-8-基)氧基]苯基]脲衍生物 | |
| CN103930425A (zh) | 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用 | |
| WO2016124160A1 (zh) | 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用 | |
| KR20230026445A (ko) | 산화아릴인 화합물 및 이의 용도 | |
| WO2018187294A1 (en) | Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof | |
| JP6909236B2 (ja) | キナゾリン誘導体またはその塩およびそれを含む医薬組成物 | |
| KR20130076046A (ko) | 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체 | |
| MX2014009524A (es) | Derivados de triazolopiridina como un inhibidor de quinasa tirosina. | |
| TWI691500B (zh) | 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物 | |
| TWI750905B (zh) | 噻唑化合物作為蛋白質激酶抑制劑 | |
| RU2772645C2 (ru) | Аминотиазольные соединения в качестве ингибиторов протеинкиназ | |
| US11299489B1 (en) | Thiazole compounds as protein kinase inhibitors | |
| KR101633722B1 (ko) | 4-(1-퍼롤-3,4-디카르복시아미드)피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
| HK40017909A (en) | Aminothiazole compounds as protein kinase inhibitors | |
| NZ759327B2 (en) | Aminothiazole compounds as protein kinase inhibitors | |
| BR112019026577B1 (pt) | Compostos aminotiazol, composição farmacêutica e uso como inibidores de proteína quinase e no tratamento de câncer | |
| HK40017909B (zh) | 作为蛋白激酶抑制剂的氨基噻唑化合物 | |
| KR20250041906A (ko) | Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210105 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210519 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210519 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210629 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210908 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210928 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20210928 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210928 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211027 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6979595 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |